Pharmacological and Therapeutic Effects of A3 Adenosine Receptor (A3AR) Agonists

Bruce T. Liang
University of Connecticut School of Medicine and Dentistry

Follow this and additional works at: https://opencommons.uconn.edu/uchcres_articles

Part of the Medicine and Health Sciences Commons

Recommended Citation
https://opencommons.uconn.edu/uchcres_articles/159
Pharmacological and Therapeutic Effects of A₃ Adenosine Receptor (A₃AR) Agonists

Pnina Fishmanᵃ, Sara Bar-Yehudaᵃ, Bruce T. Liangᵇ, and Kenneth A. Jacobsonᶜ
ᵃCan-Fite BioPharma Ltd., Kiryat-Matalon, 10 Bareket St., P.O. Box 7537, Petah-Tikva 49170, Israel
ᵇPat and Jim Calhoun Cardiology Center, University of Connecticut Health Center, Farmington, CT 06030
ᶜMolecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bldg. 8A, Rm. B1A-19, Bethesda, MD 20892-0810, Tel.: 301-496-9024, Fax: 301-480-8422, kajacobs@helix.nih.gov

Abstract

The Gᵢ-coupled A₃ adenosine receptor (A₃AR) mediates anti-inflammatory, anticancer and anti-ischemic protective effects. The receptor is overexpressed in inflammatory and cancer cells, while low expression is found in normal cells, rendering the A₃AR as a potential therapeutic target. Highly selective A₃AR agonists have been synthesized and molecular recognition in the binding site has been characterized. The present review summarizes preclinical and clinical human studies demonstrating that A₃AR agonists induce specific anti-inflammatory and anticancer effects via a molecular mechanism that entails modulation of the Wnt and the NF-κB signal transduction pathways. Currently, A₃AR agonists are being developed for the treatment of inflammatory diseases including rheumatoid arthritis and psoriasis; ophthalmic diseases such as dry eye syndrome and glaucoma; liver diseases such as hepatocellular carcinoma and hepatitis.

Keywords

G protein-coupled receptor; nucleoside; cancer; inflammation; ischemia

I. Introduction

The A₃AR is a subtype of the adenosine receptor (AR) family, which additionally includes the A₁, A₂A, and A₂B receptors [1,2]; each is encoded by a separate gene and has different physiological roles. The Gᵢ-coupled A₃AR is less widely distributed than other AR subtypes with expression in humans in lung, liver, brain, aorta, testis and heart. The utilization of the A₃AR as a therapeutic target and a biological predictive marker is based on two major findings: (a) A₃AR is overexpressed in cancer and inflammatory cells, while low expression is found in normal cells [3–5]. The high receptor expression is also found in peripheral blood mononuclear cells (PBMCs) of patients with cancer or inflammatory diseases [5,6].
(b) Highly selective A3AR agonists have been synthesized and induce specific anti-inflammatory and anticancer effects via a molecular mechanism that entails modulation of the Wnt and the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signal transduction pathways [6–8] (Figure 1). A protective effect of the agonists on normal cells was recorded as well, suggesting that this unique differential effect of the agonists will contribute to a safety profile of these drug candidates in both pre-clinical and clinical studies. Currently, A3AR agonists are being developed for the treatment of inflammatory, ophthalmic and liver diseases and demonstrate excellent safety and efficacy in Phase 2 clinical studies.

II. A3AR Agonists

The human A3AR was cloned in 1993 [1] and soon thereafter found to have cerebroprotective and cardioprotective properties [9, 10]. Like other G protein-coupled receptors (GPCRs), it is also known to affect G protein-independent signaling, such as translocation of arrestins, leading to rapid desensitization of the A3AR in vitro (typically ~20 min in the presence of agonist) [11,12]. Highly selective A3AR agonists have been synthesized, and molecular recognition in the binding site has been characterized using site-directed mutagenesis and molecular modeling. Typical A3AR agonists are adenosine derivatives that contain 5'-uronamide and N6-benzyl modifications leading to nanomolar receptor affinity (compounds numbered in bold as shown in Figure 2) [13]. The prototypical agonists IB-MECA 1 (N6-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine, CF101) and its 2-chloro analogue CI-IB-MECA 2 (2-chloro-N6-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine, CF102) are 9-ribosides with A3AR selectivity. Other selective A3 agonists include the 4'-thio derivative 3, 3'-amino-3'-deoxy derivatives CP-608,039 5 ((2S,3S,4R,5R)-3-amino-5-{6-[5-chloro-2-(3-methylisoxazol-5-ylmethoxy)benzylamino]purin-9-yl}-1-4-hydroxytetrahydrofuran-2-carboxylic acid methylamide) and its dichlorobenzyl analogue CP-532,903 4, which were originally developed for cardioprotection, and the N6-methyl-2-ethynyl derivative 6 [9,14].

Introduction of a fused bicyclic ring in the rigid analogue MRS3558 7 ((1'R,2'R,3'S,4'R,5'S)-4-{2-chloro-6-[3-bromobenzylamino]-purin-9-yl}-1-(methylaminocarbonyl)bicyclo[3.1.0]hexane-2,3-diol) increased A3AR potency and selectivity, and identified the North conformation of the ribose ring as the preferred conformation in receptor binding. 7 also shows a preference in potency for the cAMP pathway, in comparison to arrestin signaling [12]. Truncation of nucleosides at the 4'-position reduces efficacy while retaining affinity of binding to the A3AR. Thus, the methanocarba analogues MRS5147 9 ((1' R,2'R,3'S,4'R, 5'S)-4-{2-chloro-6-[3-bromobenzylamino]-purin-9-yl}-1-(methylaminocarbonyl)bicyclo[3.1.0]hexane) and its 3-ido analogue MRS5127 10 are low efficacy partial A3AR agonists, that are selective in both human and rat [15]. Recently, macromolecular conjugates (e.g. polyamidoamine dendrimers) of chemically functionalized AR agonists were introduced as potent polyvalent activators of the receptors that are qualitatively different in pharmacological characteristics in comparison to the monomeric agonists [16]. Several A3AR PET ligands have been introduced for in vivo imaging: the antagonist [18F]FE@SUPPY (5-(2-fluoroethyl) 2,4-diethyl-3-(ethylsulfanylcarbonyl)-6-phenylpyridine-5-carboxylate [16], and a pair of nucleosides, e.g. low efficacy agonist [76Br]MRS5147 9 and full agonist [76Br]MRS3581 8.

The selectivity of A3AR agonists differs between in vitro and in vivo models and between species, although the sequence identity is high (84.4%) within the transmembrane region. The characterization of a given nucleoside derivative as full or partial agonist is highly dependent on the pharmacological system, such that 2 ranges from full agonist to low efficacy partial agonist [17]. LUF6000 11 (N-(3,4-dichloro-phenyl)-2-cylohexyl-1H-imidazo[4,5-c]quinolin-4-amine) is a selective positive allosteric modulator of the human

Drug Discov Today. Author manuscript; available in PMC 2013 April 1.
A$_3$AR [18], increasing the maximal effect of inhibition of adenylate cyclase. Species-dependence of the affinity and selectivity of A$_3$AR antagonists should be carefully considered in preclinical studies. Functional polymorphism of A$_3$AR is known; a high-transcript haplotype of the A$_3$AR gene was associated with the development of cutaneous hyper-reactivity to aspirin [19].

III. Differential expression of A$_3$AR in pathological and normal cells

A$_3$AR was found to be over-expressed in various neoplastic cells including leukemia, lymphoma, astrocytoma, melanoma and pineal tumor cells, while low or almost no receptor expression was found in normal cells [20–25]. Similar data were reported in studies the receptor expression levels in tumor tissues derived from patients with colon, breast, small cell lung, pancreatic and hepatocellular carcinomas, and melanoma in direct comparison with adjacent normal tissues [3,4,6]. A direct correlation between A$_3$AR expression levels and disease progression was described in breast and colon cancer [3,4].

A similar pattern of receptor over-expression was described in inflammatory cells both in experimental animal models and humans. The most studied inflammatory disease was rheumatoid arthritis (RA) in which A$_3$AR over-expression was detected in paw tissue, draining lymph nodes and synovial cells of rats with adjuvant-induced arthritis and in synovial cells from patients with RA [7]. Similar data were observed in colon tissues derived from rats with colitis and in lungs upon inhalation of lipopolysaccharides (LPS) by mice [26,27]. The receptor was also highly expressed in anterior segment tissues derived from eyes with pseudoexfoliation syndrome in comparison to healthy subjects’ eyes [28].

The high expression levels of A$_3$AR seen in tumor and inflammatory cells were also found in PBMCs derived from tumor-bearing animals and cancer patients [3,6]. Similarly, high receptor expression levels were found in PBMCs derived from experimental animal models of inflammation and from patients with autoimmune inflammatory diseases, such rheumatoid arthritis, psoriasis and Crohn’s disease [5,7,29].

These data suggest that A$_3$AR expression levels in PBMCs mirror the receptor expression levels in the remote tumor or inflammatory tissue, rendering the receptor a biological marker. A$_3$AR upregulation is attributed to factors including elevated adenosine and cytokines, which are characteristic of the microenvironment of cancer and inflammatory cells [29,30]. Under stressed metabolic conditions, extracellular adenosine of intracellular origin accumulates in the surroundings [30,31]. Upon binding to cell surface receptors, adenosine may induce, via an autocrine pathway, the expression of its own receptors. The pro-inflammatory cytokine tumor necrosis factor-α (TNF-α), via binding to its cell surface receptor, initiates downstream signaling to result in upregulation of protein kinase B (PKB)/Akt, the inhibitor of nuclear factor of kappa light polypeptide gene enhancer in B-cells (IkB), IkB kinase (IKK) and the transcription factor NF-κB [24,28]. The latter is known to act as an A$_3$AR transcription factor. Bioinformatic analyses revealed that besides NF-κB, other transcription factors such as c-Rel, MyoD, c-fos, GR, CREB, AP-1, GATA-1, C/EBP, c-Jun and PU.1 bind to the A$_3$AR promoter region. It is well established that pro-inflammatory cytokines regulate the cell expression levels of each of these transcription factors, hence regulating A$_3$AR expression levels [5]. Taken together, it seems that receptor overexpression in tumors and inflammatory cells is a consequence and manifestation of the disease state, rather than a causative factor.

Interestingly, in vivo pharmacological data revealed that chronic treatment with A$_3$AR agonist in various experimental animal models of cancer and inflammation did not desensitize the receptor. This was evidenced by the downregulation of receptor expression levels shortly after the last drug administration in a chronic mode of treatment [6,7,32].

*Drug Discov Today. Author manuscript; available in PMC 2013 April 1.*
addition, 24 hours after the last agonist administration, A3AR protein expression level was fully recovered to the control level, demonstrating that chronic treatment does not reduce the receptor expression levels [32].

IV. In vivo pharmacological profile of A3AR agonists

A. Anticancer effect

In experimental animal models, A3AR agonists were efficacious in combating growth of solid tumors, including melanoma, prostate, colon and hepatocellular carcinoma (Table 1). The agonists showed efficacy upon chronic oral treatment, which was initiated after the tumor was already established. Overall, the drugs were much more potent in the syngeneic rather than in the xenograft models, pointing towards an immunological effect on top of the direct anticancer effect. Supporting this notion are the findings showing that treatment with 2 increased interleukin-12 and potentiated NK activity in an animal model of melanoma [33].

The direct mechanism of the anticancer effect of A3AR agonists entails modulation of the NF-κB and the Wnt signaling pathways. In tumor lesions of A3AR agonist-treated animals, the expression levels of PKB/Akt, IKK, NF-κB and TNF-α signaling proteins were downregulated. The expression of glycogen synthase kinase 3 beta (GSK-3β) was upregulated, while the expression of its downstream proteins, β-catenin, LEF1 and c-Myc, was decreased, leading to inhibition of tumor cell growth [6,32,34]. Apoptosis, an additional mechanism of action, was demonstrated in hepatocellular carcinoma tumors, and manifested by increased expression of the pro-apoptotic proteins BAD, BAX and Caspase-3 upon treatment with 2 [6]. These data prompted the selection of 2 as a drug candidate to be developed as an anticancer agent for the treatment of hepatocellular carcinoma.

B. Anti-inflammatory effect

A3AR agonists possess a robust anti-inflammatory effect mediated by the inhibition of pro-inflammatory cytokines [35–37]. 1, 2 and 3 exert anti-inflammatory effects in experimental animal models of inflammatory bowel disease, systemic toxemia, pulmonary inflammation, rheumatoid arthritis, osteoarthritis and liver inflammation (Table 2). The molecular mechanism involved with the anti-inflammatory activity entails de-regulation of the NF-κB signaling pathway, leading to inhibition of TNF-α, IL-6, IL-12, MIP-1α, MIP-2 and RANKL, resulting in apoptosis of inflammatory cells [7,38].

C. Protective effects

Chemoprotective effect—Myelotoxicity is a severe and dose-limiting complication of chemotherapy. Drug-induced myelosuppression is a major toxic factor that limits the administration of larger, potentially more effective doses of chemotherapy.

A3AR agonists administered in combination with chemotherapeutic agents to tumor-bearing mice prevented the myelotoxic effects of chemotherapy [39]. Coadministration of 1 prevented a decline in white blood cell (WBC) and neutrophil counts, resulting in full recovery of myeloid system parameters. The A3AR agonist induced production of granulocyte colony-stimulating factor (G-CSF), which stimulates myeloid progenitor cell expansion in the bone marrow and increases the WBC and neutrophil counts in the peripheral blood. The molecular mechanism underlying the events prior to G-CSF production includes the upregulation of its transcription factor NF-κB and the upstream kinases PI3K, PKB/Akt and IKK[39].

Drug Discov Today. Author manuscript; available in PMC 2013 April 1.
In the cardiovascular system, A3AR agonists induce cardioprotection against chemotherapy-induced damage. The anthracycline antibiotic doxorubicin (DOX) or adriamycin has been an effective treatment for leukemias, lymphomas and solid tumors including breast cancer. Acute cardiotoxicity of DOX develops during and shortly after the initiation of therapy. However, chronic or late DOX-induced cardiotoxicity has a latency lasting for years prior to the development of overt heart failure. Currently, only dexrazoxane, a free-radical scavenger, shows promise as a cardioprotective agent during DOX treatment [40]. Developing new methods to reduce both acute and chronic cardiotoxicity should increase the effectiveness of this anticancer therapy.

In this context, it is interesting to note that the A3 agonist 2 can protect against mitochondrial damage and helps preserve ATP production in cultured rat cardiomyocytes. Repeated i.v. injection of 2 prior to DOX administration in rats helped prevent left ventricular wall thinning and dysfunction [41,42]. Whether continuous treatment with 2 can delay or prevent the late DOX cardiotoxicity is unknown.

**Cardioprotective anti-ischemic effect**—A3AR agonists protect against myocardial ischemia/reperfusion injury (I/R), which has been demonstrated using selective agonists and A3AR-knockout mice, which are otherwise physiologically normal [43]. The cardioprotective effect is evident in role of the A3AR in ischemic preconditioning and in direct protection during ischemia. The A3AR may also be involved in mediating the post-conditioning effect given its ability to reduce infarct size when it is administered during reperfusion [9]. The A3AR has the lowest level of myocardial expression among the ARs, at least for the murine heart. However, evidence has accumulated indicating that stimulation of an endogenous cardiac A3AR, independent of circulating immune inflammatory cells or resident mast cells, can result in cardioprotection [44]. An anti-inflammatory action of the A3AR in vivo may also contribute importantly to the cardioprotective effect of A3 agonist. Both a direct cardioprotective mechanism and an anti-inflammatory effect exerted at the immune cell level in vivo may be important. Future studies are needed to address this question. A cardioprotective role of the A3AR was also found in non-rodent mammals such as rabbits and dogs [45,46].

Mediators for a direct myocardial protective effect include protein kinase C (PKC), KATP channels, reactive oxygen species, connexin 43, mitochondrial permeability transition pore (MPTP), and GSK-3β. Thus, a signaling cascade may begin with A3AR stimulation, PKC activation, phosphorylation (and thus inactivation) of GSK-3β, leading to inhibition of MPTP and reduced cardiac myocyte death [47]. The role of sarcolemmal vs. that of mitochondrial KATP channels in mediating the A3 cardioprotection is not clear. There is extensive evidence for a protective role of mitochondrial KATP (mito KATP) channel including the recently elucidated function of connexin 43 in mediating mito KATP opening by PKC. A recent study, however, showed that sarcolemmal KATP deletion abrogated the preconditioning effect of A3AR agonist in murine heart [43]. Given the redundancy of signaling pathways causing cardioprotection, it is possible that species differences exist in the role of such signaling molecules. Genetic background could also modulate cardioprotection not only in mice but also humans.

**Protection of skeletal muscle**—A3AR agonists attenuate skeletal muscle injury caused by ischemia and reperfusion or eccentric exercise [48]. Skeletal muscle is susceptible to various forms of injury, including ischemia, trauma, and physical exertion. Skeletal muscle is one of the most vulnerable tissues in the extremities. Developing new methods designed to provide cytoprotection to the skeletal muscle is thus important. Direct infusion of adenosine can mimic the skeletal muscle protective effect of ischemic preconditioning in extensor digitorum longus muscle before aorta occlusion in the rat as well as in the pig.
latissimus dorsi muscle flap model. A\textsubscript{3}AR agonist, when administered \textit{in vivo}, signals selectively via phospholipase PLC\textsubscript{β}2/\textsubscript{β}3 to cause a reduction in skeletal muscle injury sustained either during ischemia/reperfusion or eccentric exercise [48]. While A\textsubscript{1} and A\textsubscript{2A}Rs can also mediate anti-ischemic protection in skeletal muscle, only the A\textsubscript{3}AR can induce protection against both I/R and eccentric exercise injuries.

Given that activation of the A\textsubscript{3}AR has a known anti-inflammatory effect, it is possible that skeletal muscle protective effect is mediated, at least, in part at an immune cell level. The following lines of evidence support this hypothesis. First, activated mast cells and neutrophils are important contributors of skeletal muscle ischemia/reperfusion damage. Second, activation of the A\textsubscript{3}AR can block superoxide formation and chemotaxis of murine bone marrow neutrophils [49].

**Lung ischemia/reperfusion protection**—A\textsubscript{3}AR agonist prevents lung injury following ischemia/reperfusion in the cat. Compound 3 produced a sustained protection, which was associated with suppressed p38 protein expression and downregulation of its phosphorylation [50,51].

**Neuroprotection**—Evidence from diverse models suggests that neuroprotective effects may be mediated by the A\textsubscript{3}AR, but differences between acute and chronic agonist administration have been noted [10]. Ischemic brain injury in a model of forebrain ischemia in gerbils is reduced upon chronic treatment with 1 [52]. A\textsubscript{3}AR agonist was found to prevent the loss of retinal ganglion cells following activation of the P2\times7 receptor in a rat experimental model [53].

**V. CF101 for the treatment of inflammatory and ophthalmic diseases**

Based on the pre-clinical pharmacology data and encouraging safety data in Phase I studies [54], the anti-inflammatory effect of 1 was tested in a set of three Phase II clinical studies including rheumatoid arthritis (RA), psoriasis and dry eye syndrome (Table 3). Overall, the data obtained from these clinical studies showed excellent safety profile and efficacy, positioning 1 as a disease-modifying anti-inflammatory drug.

**A. Rheumatoid Arthritis**

A chronic, systemic inflammatory disorder attacking the joints resulting in inflammatory synovitis that may progress to the destruction of articular cartilage and bone [55]. The mechanisms responsible for causing joint damage and functional impairment in RA are complicated and involve B cell or T cell products stimulating the release of TNF and other pro-inflammatory cytokines, including interleukin-1, interleukin-6, and TNF-α and degradative enzymes.

In a multi-center Phase II study, blinded to dose (0.1, 1.0, or 4.0 mg), the drug was administered orally, twice daily for 12 weeks to patients with active RA. The primary efficacy endpoint was an improvement of 20% or more according to the classification of RA responses by the American College of Rheumatology (ACR) [55]. Compound 1 was found to be safe and well tolerated, and the maximal responses were observed in patients treated with a 1.0 mg dose. At 12 weeks, 55.6%, 33.3%, and 11.5% of the patients receiving 1.0 mg 1 achieved ACR20%, 50%, and 70% responses, respectively. In addition, a statistically significant correlation between A\textsubscript{3}AR expression at baseline and patient response to 1 was observed, rendering the A\textsubscript{3}AR as a biological predictive marker [56].
B. Psoriasis

A chronic inflammatory skin disease characterized by epidermal hyper-proliferation and immature differentiation resulting in multisystem pathology and a negative impact on the quality of life of the patients [57]. Pro-inflammatory cytokines, such as INF-γ, TNF-α, IL-23 and Th17 are known to play a role in mediating the inflammation and epidermal alterations in psoriasis [58].

The efficacy and safety of 1 were tested in a Phase II, multicenter, randomized, double blind, dose-ranging, placebo-controlled study in patients with moderate-to-severe chronic plaque-type psoriasis. Compound 1 (1, 2, or 4 mg) or placebo was administered orally twice daily for 12 weeks. Overall, the drug was safe and well tolerated.

The maximal improvement in the mean change from baseline in the PASI (psoriasis area and severity index) score vs. placebo and the highest percentage of patients who achieved PGA (physician’s global assessment) score of 0 or 1 were observed in the 2 mg 1-treated group. The improvement was progressive and linear throughout the study period. Thus, 1 was safe and well tolerated.

C. Dry Eye Syndrome

An inflammatory condition of the eye that is caused by decreased tear production or increased tear film evaporation. It is characterized by massive production of pro-inflammatory cytokines. The dryness and the inflammation could result in eye damage leading to impaired vision [59,60].

Anecdotal findings demonstrating that 1 improved indicators of dry eye syndrome in RA patients led to a separate randomized, multi-center, doubled-masked, placebo-controlled, parallel-group, Phase II clinical study of the safety and efficacy of 1 (1 mg) administered orally daily for 12 weeks to patients with moderate-to-severe dry eye syndrome. Compound 1 was safe and well tolerated and no serious adverse events were noted throughout the study. Treatment with 1 resulted in a statistically significant improvement in the mean change from baseline at week 12 of the clearance of corneal staining, tear break-up time and tear meniscus height in the group treated with 1 vs. placebo. Compound 1 was well tolerated and exhibited an excellent safety profile with no serious adverse events. Interestingly, a statistically significant decrease from baseline was observed in the intraocular pressure of the 1-treated patients in comparison to the placebo-treated group [61].

No serious adverse events in the RA, psoriasis or dry eye clinical studies were observed. The profile of the adverse events was similar between the placebo and 1-treated groups.

VI. Conclusions

Based on the experimental animal data and human clinical study results presented in the current review, A3AR is suggested as a specific and unique therapeutic target to combat proliferative diseases including inflammation and cancer. The excellent safety profile of A3AR agonists, currently tested in human clinical studies, is attributed to the different protective effects mediated via the receptor. The A3AR has also been identified as a biological marker to predict a patient’s eligibility for treatment with the agonists. Taken together, the utilization of A3AR as both a biological predictive marker and a therapeutic target encompass the a ‘personalized medicine’ approach and make A3AR agonists promising small molecule drug candidates.
Acknowledgments

We thank the Intramural Research Program of the NIH, National Institute of Diabetes and Digestive and Kidney Diseases and the Ray Neag Distinguished Professorship (to BTL).

References


Figure 1.
Signaling pathways involved in the action of A3AR agonists. Pathways proposed to be involved in anticancer, antiinflammatory, and cardioprotective effects of A3AR agonists. A3AR signals through both G protein-dependent (via Gi or β,γ subunits) and independent pathways. Translocation of arrestin to the A3AR would be associated with receptor downregulation [22] and G protein-independent signaling. Not all pathways are present in all circumstances, and other pathways not shown can also affect cell survival, proliferation, and differentiation. In cancer (blue arrows), activation of the A3AR corrects an imbalance in the downstream Wnt signaling pathway [6,34]. Administration of an A3 agonist to activate its cell surface receptor inhibits the formation of cAMP and indirectly decreases
phosphorylation (and therefore decreased inactivation) of the serine/threonine kinase GSK-3β. The resulting increased phosphorylation of β-catenin causes it to be removed from the cytoplasm by ubiquitination and therefore preventing its nuclear import. This results in a net suppression of cyclin D1 and c-myc, which leads to cell growth inhibition. With respect to cancer, NF-κB is a potent anti-apoptotic agent in malignant cells and its activation is strongly associated with tumors [76]. Additionally, as a major cell survival signal, NF-κB is involved in multiple steps in carcinogenesis and in cancer cells’ resistance to chemo- and radiotherapy. Thus, drugs aimed to decrease expression or activity of NF-κB could abrogate its anti-apoptotic effect. In inflammatory models [7,8,9,20,29,71], the reduced activation of NF-κB (in synoviocytes, neutrophils, and other immune cells) has an antiinflammatory effect, in part by reducing the expression of TNF-α. Opposite effects of A3AR activation on some of these pathways (green arrows) are associated with myeloprotective (via increased NF-κB in splenocytes [39]) and cardioprotective (GSK-3β inhibition [47]) responses to A3AR agonists. In the heart, there are opposing effects of GSK-3β at different stages of prolonged ischemia (GSK-3β protects) and reperfusion (GSK-3β inhibition protects) [77].
Figure 2.
Representative agonists (1 – 8) and partial agonists (9, 10) of nanomolar affinity at the A$_{3}$AR and a positive allosteric modulator 11. Nucleosides 7 – 10 contain the (North) methanocarba substitution of the ribose ring, which maintains an A$_{3}$AR-preferred conformation.
Table 1

Effects of A3AR agonists on growth of solid tumors in experimental animal models.

<table>
<thead>
<tr>
<th>Inflammatory Condition</th>
<th>Experimental animal model</th>
<th>Refs.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rheumatoid arthritis</td>
<td>Adjuvant &amp; collagen-induced arthritis</td>
<td>[7, 38, 68–70]</td>
</tr>
<tr>
<td>Osteoarthritis</td>
<td>Monosodium iodoacetate-induced osteoarthritis</td>
<td>[71]</td>
</tr>
<tr>
<td>Inflammatory bowel diseases</td>
<td>Dextran sodium sulphate or 2,4,6-trinitrobenzene sulfonic acid-induced colitis; Spontaneous colitis in interleukin-10 gene deficient mice</td>
<td>[26, 37, 72]</td>
</tr>
<tr>
<td>Uveitis</td>
<td>IRBP induced Experimental autoimmune uveitis</td>
<td>[73]</td>
</tr>
<tr>
<td>Sepsis/toxemia</td>
<td>CLP and LPS-induced sepsis</td>
<td>[35, 74]</td>
</tr>
<tr>
<td>Pulmonary inflammation</td>
<td>LPS inhalation</td>
<td>[27]</td>
</tr>
</tbody>
</table>
Table 2

Effects of A3AR agonists in experimental animal models of inflammatory disease.

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>Animal strain, Cell line</th>
<th>Experimental model</th>
<th>Refs.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melanoma</td>
<td>Mice; B16-F10</td>
<td>Syngeneic; Metastatic</td>
<td>[33, 62, 63]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Syngeneic; subcutaneous</td>
<td></td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>Rat; AT6.1 Mice; PC3</td>
<td>Xenograft; Metastatic</td>
<td>[32, 64]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Xenograft, subcutaneous</td>
<td></td>
</tr>
<tr>
<td>Colon carcinoma</td>
<td>Mice; HCT-116 Mice; CT-26</td>
<td>Xenograft, subcutaneous</td>
<td>[34, 65, 66]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Syngeneic; Metastatic</td>
<td></td>
</tr>
<tr>
<td>Breast cancer</td>
<td>Mice; SK-BR-3</td>
<td>Xenograft, subcutaneous</td>
<td>[75]</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>Rat; N1S1 Mice; Hep3B</td>
<td>Syngeneic; Orthotopic</td>
<td>[6, 67]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Xenograft, subcutaneous</td>
<td></td>
</tr>
</tbody>
</table>
Table 3
Past and present human clinical studies utilizing CF101 and CF102.

<table>
<thead>
<tr>
<th>Disease</th>
<th>Phase</th>
<th>Primary endpoints</th>
<th>Refs.</th>
<th>Current status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rheumatoid arthritis</td>
<td>2a</td>
<td>ACR20 response at week 12</td>
<td>[56]</td>
<td>Phase 2b</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>2</td>
<td>Reduction in PASI score of at least 75% from Baseline (PASI 75) to the end of the 12 weeks treatment period</td>
<td>[57]</td>
<td>Phase 2/3</td>
</tr>
<tr>
<td>Dry eye syndrome</td>
<td>2</td>
<td>Improvement of 25% or more over baseline at week 12 in tear film BUT or in superficial punctate keratitis as assessed by either FS or ST1 results</td>
<td>[60]</td>
<td>Phase 3</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>1/2</td>
<td>To determine the safety, tolerability, dose-limiting toxicities, maximum tolerated dose, recommended Phase 2 dose and to assess the repeat-dose pharmacokinetic behavior of orally administered CF102</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>Hepatitis C virus infection</td>
<td>1/2</td>
<td>To determine the safety and tolerability of 15 days of orally administered CF102 in patients with chronic hepatitis C genotype 1, to assess the effects on HCV load during 24 weeks and to assess the repeat-dose pharmacokinetic behavior of CF102</td>
<td></td>
<td>Ongoing</td>
</tr>
</tbody>
</table>

FS = fluorescein staining ST1 = Schirmer shear test 1